文献速递贫血与红细胞疾病

重新审视镰状细胞病中的贫血:在治疗策略中寻求平衡

Revisiting anemia in sickle cell disease and finding the balance with therapeutic approaches.
PubMed 文献 · Blood · 2022-01-01

本文探讨镰状细胞病(SCD)中贫血的复杂病理生理机制,指出贫血既与多器官损伤相关,也可能降低黏滞度相关并发症风险;在现有治疗格局下,需平衡提升血红蛋白水平与增加血液黏滞度之间的潜在风险。

要点

  • 贫血在SCD中不仅反映红细胞量减少,还涉及红细胞破坏和游离血红蛋白释放,参与多器官损伤。
  • 贫血虽与不良结局相关,但可能降低黏滞度相关并发症风险。
  • SCD药物开发以往以血管闭塞危象频率为终点,现日益关注慢性贫血对结局的影响。

核心结论

  • 本文旨在探讨SCD贫血的复杂病理生理机制,以及在当前治疗格局下平衡提升血红蛋白与增加血液黏滞度风险的必要性。

研究设计与样本

  • 本文为综述,旨在探讨SCD中贫血的病理生理机制及治疗平衡问题。

主要发现

  • 慢性溶血性贫血和间歇性急性疼痛发作是SCD的两大特征。
  • 贫血信号红细胞量和氧输送减少,也反映持续红细胞破坏和游离血红蛋白释放,共同参与多器官损伤发病机制。
  • 贫血虽与许多不良结局相关,但可能降低黏滞度相关并发症风险。
  • SCD药物开发以往主要针对减少血管闭塞危象频率,现日益关注慢性贫血对不良结局的贡献。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic hemolytic anemia and intermittent acute pain episodes are the 2 hallmark characteristics of sickle cell disease (SCD). Anemia in SCD not only signals a reduction of red cell mass and oxygen delivery, but also ongoing red cell breakdown and release of cell-free hemoglobin, which together contribute to a number of pathophysiological responses and play a key role in the pathogenesis of cumulative multiorgan damage. However, although anemia is clearly associated with many detrimental outcomes, it may also have an advantage in SCD in lowering risks of potential viscosity-related complications. Until recently, clinical drug development for SCD has predominantly targeted a reduction in the frequency of vaso-occlusive crises as an endpoint, but increasingly, more attention is being directed toward addressing the contribution of chronic anemia to poor outcomes in SCD. This article aims to explore the complex pathophysiology and mechanisms of anemia in SCD, as well as the need to balance the benefits of raising hemoglobin levels with the potential risks of increasing blood viscosity, in the context of the current therapeutic landscape for anemia in SCD.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Xu JZ, Thein SL. Revisiting anemia in sickle cell disease and finding the balance with therapeutic approaches. Blood. 2022. PMID: 35587865. doi:10.1182/blood.2021013873

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。